173 Diagnostic utility of molecular and imaging biomarkers 2 Table 35. Estimated pooled test performance of the Afirma® GEC in indeterminate thyroid nodules ni nH TP FP FN TN malignant (TP+FN/ni) sensitivity (95% CI), % specificity (95% CI), % LR+ (95% CI) LR- (95% CI) Alexander 2012 210 210 46 77 5 82 32% 90 (79-97) 52 (44-60) 1.86 (1.55-2.24) 0.19 (0.08-0.44) Alexander 2014 326 124 47 66 1* 10* 16% 98 (89-100) 13 (6-23) 1.13 (1.02-1.24) 0.16 (0.02-1.20) Harrell 2014 58 35 17 13 2 3 33% 89 (67-99) 19 (4-46) 1.10 (0.83-1.46) 0.56 (0.11-2.96) Lastra 2014 132 50 22 26 0 2 46% 100 (85-100) 7 (1-24) 1.07 (0.94-1.22) 0.25 (0.01-5.00) McIver 2014 72 36 5 27 1 3 10% 83 (36-100) 10 (2-27) 0.93 (0.63-1.35) 1.67 (0.21-13.43) Sullivan 2014 14 7 2 4 0 1 15% 100 (16-100) 20 (1-72) 1.11 (0.56-2.20) 0.67 (0.04-11.94) Brauner 2015 72 46 6 37 0 3 8% 100 (54-100) 8 (2-20) 1.02 (0.81-1.27) 0.84 (0.05-14.50) Celik 2015 40 20 10 8 0 2 50% 100 (69-100) 20 (3-56) 1.24 (0.87-1.75) 0.20 (0.01-3.70) Marti 2015 165 70 27 36 0 7 16% 100 (87-100) 16 (7-31) 1.18 (1.03-1.37) 0.10 (0.01-1.76) Noureldine 2015 222 183 72 99 2 10 35% 97 (91-100) 9 (4-16) 1.07 (1.00-1.15) 0.29 (0.07-1.31) Witt 2016 32 15 6 9 0 0 21% 100 (54-100) 0 (0-34) 0.98 (0.76-1.25) 1.43 (0.03-63.80) Wu 2016 214 95 50 31 2 12 24% 96 (87-100) 28 (15-44) 1.33 (1.10-1.62) 0.14 (0.03-0.58) Yang 2016 189 67 32 30 0 5 17% 100 (89-100) 14 (5-30) 1.16 (1.01-1.34) 0.10 (0.01-1.73) POOLED RESULTS 1,746 958 342 463 13 140 20.3% 97.3 (94.2-98.8) 15.0 (9.5-22.9) 1.15 (1.06-1.23) 0.18 (0.09-0.37) *: may include ≥1 and ≤4 nodules with Bethesda V cytology, that were not clearly distinguished in the article. FN: false negative. FP: false positive. LR+: positive likelihood ratio. LR-: negative likelihood ratio. nH: number of indeterminate thyroid nodules with conclusive index test and available histopathology. ni : number of indeterminate nodules. TN: true negative. TP: true positive.
RkJQdWJsaXNoZXIy MTk4NDMw